What is Tactile Systems Technology Inc?
, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.
TCMD · Verdict
Solid reward · low risk
TCMD scores well on balance sheet and cash flow with no major weaknesses flagged in the model.
Based on 88% data coverage
TCMD · Verdict
Interest covered 28.2×
12% free-cash-flow margin
Revenue +10.1% CAGR
6% net margin · 9% ROE
Model-based scoring. For information only — not financial advice.
, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 657.24M, and a P/E ratio of 35.7x.
The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.